[Hengrui Medicine: The marketing application for Ruikang trastuzumab for injection was accepted and included in the priority review] On October 29, Hengrui Medicine (600276.SH) announced that the company's subsidiary Suzhou Shengdia Biopharmaceutical Co., Ltd. received the "Notice of Acceptance" from the State Food and Drug Administration, and the drug marketing authorization application for Ruikang trastuzumab for injection was accepted and included in the priority review process. The proposed indication is for the first-line treatment of patients with locally advanced or metastatic HER2-positive breast cancer, with or without pertuzumab. This drug is an antibody-conjugated drug targeting HER2 independently developed by the company, and has been approved for three indications in China. Up to now, the cumulative R&D investment in related projects is approximately 2.361 billion yuan.